Skip to main content

Table 2 EGFR Positivity by Study Subgroup

From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

Characteristic, n= 357 EGFR neg EGFR pos P
  (score 0) (score 1-3+) Value
  n (%) n (%)  
Female, 143 79 (55) 64 (45)  
Male, 214 126 (59) 88 (41) .69
Age,    
>65, 173 96 (55) 77 (45)  
≤65, 181 107 (59) 74 (41) .698
ECOG performance status,    
0-1, 326 186 (57) 140 (43)  
2, 22 11 (50) 11 (50) .697
Not specified, 9 8 (89) 1 (11)  
Primary tumor location    
Gastroesophageal junction, 107 60 (56) 47 (44)  
Mid to distal stomach, 231 132 (57) 99 (43) .916
Not specified, 19 13 (68) 6 (32)  
Disease status    
Stage IV at diagnosis, 298 171 (57) 127 (43)  
Recurrent disease, 59 34 (58) 25 (42) 1
Metastatic disease sites    
Liver, present, 157 85 (54) 72 (46)  
Liver, not present, 199 119 (60) 80 (40) .559
Lymph nodes, present 219 127 (58) 92 (42)  
Lymph nodes, not present, 98 51 (52) 47 (48) .585
Peritoneum, present ,93 57 (61) 36 (39)  
Peritoneum, not present, 263 147 (56) 116 (44) .58
Lauren classification,    
Diffuse/mixed, 170 107 (63) 63 (37) .211
Intestinal, 139 72 (52) 67 (48)  
Not specified, 48 26 (54) 22 (46)  
Specimen used for EGFR testing    
Biopsy, 238 141 (59) 97 (41)  
Surgical specimen,116 62 (53) 54 (47) .538
Not specified, 3 2 (67) 1 (33)  
Primary tumor, 298 173 (58) 125 (42)  
Metastatic lesion, 50 24 (48) 26 (52) .418
Not specified, 9 9 (100) 0